Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H37NO12 |
Molecular Weight | 627.6357 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]1(CCCCO1)O[C@H]2[C@@H](N)C[C@H](O[C@@]3([H])C[C@@](O)(CC4=C(O)C5=C(C(=O)C6=C(C=CC=C6OC)C5=O)C(O)=C34)C(=O)CO)O[C@H]2C
InChI
InChIKey=KMSKQZKKOZQFFG-YXRRJAAWSA-N
InChI=1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21+,22-,31+,32-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/3046496Curator's Comment: description was created based on several sources, including:
https://newdrugapprovals.org/2015/06/01/pirarubicin-hydrochloride/ | http://www.kegg.jp/medicus-bin/japic_med_product?id=00053425-001#00053425-001
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3046496
Curator's Comment: description was created based on several sources, including:
https://newdrugapprovals.org/2015/06/01/pirarubicin-hydrochloride/ | http://www.kegg.jp/medicus-bin/japic_med_product?id=00053425-001#00053425-001
Pirarubicin is a new kind of anthracene nucleus broad-spectrum antitumor antibiotic. This compound was rapidly incorporated into tumor cells, inhibiting DNA polymerase alpha, DNA topoisomerase II and subsequently DNA synthesis. Inhibition of RNA synthesis was also noted. It is indicated as an antineoplastic agent for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer, ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. Among the side effects, cardiac toxicity, alopecia and disturbance of the digestive organs were mild.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1828 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Pinorubin Approved UseIt is indicated for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer (bladder, renal, ureter neoplasms), ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. |
|||
Primary | Pinorubin Approved UseIt is indicated for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer (bladder, renal, ureter neoplasms), ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. |
|||
Primary | Pinorubin Approved UseIt is indicated for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer (bladder, renal, ureter neoplasms), ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. |
|||
Primary | Pinorubin Approved UseIt is indicated for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer (bladder, renal, ureter neoplasms), ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. |
|||
Primary | Pinorubin Approved UseIt is indicated for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer (bladder, renal, ureter neoplasms), ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. |
|||
Primary | Pinorubin Approved UseIt is indicated for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer (bladder, renal, ureter neoplasms), ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. |
|||
Primary | Pinorubin Approved UseIt is indicated for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer (bladder, renal, ureter neoplasms), ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. |
|||
Primary | Pinorubin Approved UseIt is indicated for the treatment of the following diseases: head and neck cancer, breast cancer, gastric cancer, urothelial cancer (bladder, renal, ureter neoplasms), ovarian cancer, uterine cancer, acute leukemia, malignant lymphoma. |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ndrugs.com/?s=pinorubin&t=dosage
25-50 mg/m2 BSA every 3-4 wk, to be given as injection over 5-10 minutes into a rapidly-flowing infusion of glucose 5%
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10470291
The IC50 values of Pirarubicin in M5076 ovarian sarcoma cells was 0.366 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QL01DB08
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
||
|
FDA ORPHAN DRUG |
778820
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
||
|
WHO-ATC |
L01DB08
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
||
|
NCI_THESAURUS |
C1594
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB09894MIG
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
11296583
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
C1197
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
100000081658
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
D58G680W0G
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
m8871
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB11616
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
DTXSID2046755
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
5877
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
CHEMBL1398373
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
72496-41-4
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
PIRARUBICIN
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
2198
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | |||
|
33764
Created by
admin on Sat Dec 16 05:10:56 GMT 2023 , Edited by admin on Sat Dec 16 05:10:56 GMT 2023
|
PRIMARY | RxNorm |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)